2022
Exports
$64.2MWorld Rnk 44 / 208
Flag Rnk 151 / 1211
2022
PRODUCT COMPLEXITY IN Vaccines, blood, antisera, toxins and cultures
1.38Rnk 75 / 1025
2022
Imports
$435MWorld Rnk 59 / 225
Flag Rnk 17 / 1209
2022
ECONOMIC COMPLEXITY of Bulgaria
0.68Rnk 38 / 133

About

Exports In 2022, Bulgaria exported $64.2M in Vaccines, blood, antisera, toxins and cultures, making it the 44th largest exporter of Vaccines, blood, antisera, toxins and cultures in the world. At the same year, Vaccines, blood, antisera, toxins and cultures was the 151st most exported product in Bulgaria. The main destination of Vaccines, blood, antisera, toxins and cultures exports from Bulgaria are: Iran ($8.66M), Germany ($7.07M), Japan ($6.78M), Romania ($6.27M), and South Korea ($4.26M).

The fastest growing export markets for Vaccines, blood, antisera, toxins and cultures of Bulgaria between 2021 and 2022 were Iran ($8.65M), Romania ($5.75M), and Japan ($5.42M).

Imports In 2022, Bulgaria imported $435M in Vaccines, blood, antisera, toxins and cultures, becoming the 59th largest importer of Vaccines, blood, antisera, toxins and cultures in the world. At the same year, Vaccines, blood, antisera, toxins and cultures was the 17th most imported product in Bulgaria. Bulgaria imports Vaccines, blood, antisera, toxins and cultures primarily from: Germany ($149M), Switzerland ($92.9M), Hungary ($39.6M), Belgium ($37.9M), and Netherlands ($33.4M).

The fastest growing import markets in Vaccines, blood, antisera, toxins and cultures for Bulgaria between 2021 and 2022 were Slovenia ($12.2M), Switzerland ($11.8M), and Ireland ($4.86M).

Latest Trends

Oct 2024

Subnational Monthly Trade

View
Flow
Y-AXIS SCALE

For a full breakdown of trade patterns, visit the trend explorer or the product in country profile.

The following visualization shows the latest trends on Vaccines, blood, antisera, toxins and cultures. Countries are shown based on data availability.

* Using January 2020 exchange rates when trade data is reported in local currency.

Explore Latest Trends

Subscribe today to OEC pro and access the latest data

Sign Up

Historical Data

Trade Balance

Color
EXPORTS (2022)$64.2M
IMPORTS (2022)$435M
NET TRADE (2022)-$371M

In 2022, Bulgaria exported $64.2M in Vaccines, blood, antisera, toxins and cultures. The main destinations of Bulgaria exports on Vaccines, blood, antisera, toxins and cultures were Iran ($8.66M), Germany ($7.07M), Japan ($6.78M), Romania ($6.27M), and South Korea ($4.26M).

In 2022, Bulgaria imported $435M in Vaccines, blood, antisera, toxins and cultures, mainly from Germany ($149M), Switzerland ($92.9M), Hungary ($39.6M), Belgium ($37.9M), and Netherlands ($33.4M).

Explore Visualizations

Export Destinations (2022)

Import Origins (2022)

Market Growth

Flow
THE FASTEST GROWING Vaccines, blood, antisera, toxins and cultures EXPORT MARKETS FOR Bulgaria WERE (2021 - 2022):
Iran$8.65M (105k%)
Romania$5.75M (1.1k%)
Japan$5.42M (398%)
THE FASTEST DECLINING MARKETS FOR THE EXPORT OF Vaccines, blood, antisera, toxins and cultures BY Bulgaria WERE (2021 - 2022):
Turkey-$7.99M (-89.9%)
Italy-$7.26M (-98.8%)
Norway-$2.29M (-100%)

Change in Exports by Market (2021 - 2022)

Market Concentration

View
Flow
Type
In 2022, Bulgaria's main exporting competitors in Vaccines, blood, antisera, toxins and cultures were:
In 2022, Bulgaria's main importing competitors in Vaccines, blood, antisera, toxins and cultures were:

Explore Visualizations

Trade Value of Vaccines, blood, antisera, toxins and cultures by Exporters

Potential Exports

Potential Exports

Flow
View
TOP EXPORT POTENTIALGermany+ $13M
TOP IMPORT POTENTIALBelgium+ $22.4M

Vaccines, blood, antisera, toxins and cultures’s highest export potential is Germany. With an export gap of $13M.   Vaccines, blood, antisera, toxins and cultures’s highest import potential is Belgium with an import gap of $22.4M.

See methodology.

Subscribe today to OEC pro and access the latest data

Sign Up

Have questions, comments, or concerns?
Send us an e-mail: support@oec.world
Follow @OECtoday on
Created, Designed, and Developed by:
In collaboration with